Featured
Large Chinese Pharma / HRG2010
¥84.2 Million, 84 Centers, $328 Million: Hengrui Took a Drug With No Story All the Way to Filing
HRG2010, Hengrui's carbidopa/levodopa IR/ER capsule for Parkinson's motor fluctuations, never made the company's launch forecast or pipeline appendix — yet quietly finished Phase 3 across 84 centers and filed for approval on August 24, 2026.
Large Chinese Pharma / SHR-1819
SHR-1819 Files for Approval: The Sixth Ticket In
September 26, 2026 · 20 min readLarge Chinese Pharma / adebrelimabAdebrelimab: a PD-L1 that "doesn't rely on standing out on its own" — how Hengrui uses it to thicken its portfolio
Sep 26, 2026 · 17 min readLarge Chinese Pharma / BHB-1893One Molecule, Two Names, Two Destinies
Sep 26, 2026 · 21 min readLatest
No articles match your search.
Series
View all series →23 articles
Large Chinese Pharma
Pipeline and filing analysis on Hengrui and the other large domestic sponsors.
Browse →14 articlesChinese Biotech
Asset-level deep dives on China-originated drugs, built from filings and trial registries.
Browse →7 articlesBD Deals & Industry Events
Deals, JVs and industry events reshaping the China pharma landscape.
Browse →3 articlesChina-Originated Assets Licensed to MNCs
China-originated assets licensed out to multinationals — deal terms and development strategy.
Browse →